You are here: Industry Insights > Lynparza

News List

AstraZeneca, Merck & Co.'s PARP inhibitor Lynparza gains EU approval in breast cancer firstwordpharma
April 10, 2019
AstraZeneca and Merck & Co. announced Wednesday that the European Commission approved Lynparza (olaparib) ……
AZ/Merck & Co’s Lynparza delays spread of pancreatic cancer pharmaphorum
February 27, 2019
AstraZeneca and Merck & Co’s Lynparza could offer a new option for certain patients with pancreatic cancer after a trial showed it slowed progression of the disease.
AstraZeneca announces positive results from SOLO-3 trial of Lynparza pharmaceutical-technology
December 21, 2018
AstraZeneca and its partner Merck have published positive results from SOLO-3 phase III trial of Lynparza, which is indicated for BRCA-mutated (BRCAm) advanced ovarian cancer.
Lynparza gets FDA approval for ovarian cancer pharmatimes
December 21, 2018
AstraZeneca and MSD have announced that Lynparza (olaparib) has been given the green light by the FDA for first-line maintenance therapy of BRCA-mutated advanced ovarian cancer, further expanding the drug's reach.
Lynparza Approved by FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer americanpharmaceuticalreview
December 20, 2018
AstraZeneca and Merck announced the US Food and Drug Administration (FDA) has approved Lynparza for the maintenance treatment of adult patients with deleterious or......
FDA grants priority review to AstraZeneca, Merck & Co.'s filing for Lynparza in first-line maintenance setting for ovarian cancer firstwordpharma
November 13, 2018
AstraZeneca and Merck & Co. said Monday that the FDA granted priority review to a filing seeking approval of Lynparza (olaparib) as a maintenance treatment for patients with newly diagnosed, BRCA-mutated advanced ovarian cancer who are in complete or part
FDA grants priority review to AstraZeneca, Merck & Co.'s filing for Lynparza in first-line maintenance setting for ovarian cancer firstwordpharma
November 13, 2018
AstraZeneca and Merck & Co. said Monday that the FDA granted priority review to a filing seeking approval of Lynparza (olaparib) as a maintenance treatment for patients with newly diagnosed, BRCA-mutated advanced ovarian cancer who are in complete or part
AstraZeneca, Merck's Lynparza scores speedy review in blockbuster ovarian cancer market fiercepharma
November 13, 2018
Last month, AstraZeneca and Merck’s Lynparza posted big-time ovarian cancer data, and regulators are taking note.
NICE provisionally knocks back AstraZeneca's PARP inhibitor Lynparza in ovarian cancer maintenance setting pharmafile
November 12, 2018
The National Institute for Health and Care Excellence (NICE) issued draft guidance Friday recommending against routine NHS funding of AstraZeneca's Lynparza (olaparib) for
AZ/MSD’s Lynparza assigned Orphan status in US pharmatimes
November 01, 2018
AstraZeneca and MSD’s PARP inhibitor Lynparza has been granted orphan drug designation in the US for the treatment of pancreatic cancer.

Previous page 1 2 3 4 5 6 7 Next page